平均减重17% 司美格鲁肽减肥药正式在中国上市
稀土掘金
发表于 2024-11-17 15:08:37
193
0
0
诺和盈有严格的使用指征。使用者的初始体重指数(BMI)必须符合以下条件:大于等于30kg/m²(肥胖),或在27kg/m²至30kg/m²(超重)之间,且存在至少一种体重相关合并症(例如高血糖、高血压、血脂异常、阻塞性睡眠呼吸暂停或心血管疾病等)。据了解,诺和盈能够实现平均约17%的体重降幅。
针对大众普遍关注的定价以及药品供应问题,在17日举行的诺和盈全国上市会上,诺和诺德方面对包括《每日经济新闻》记者在内的多家媒体表示,公司已经开始申请诺和盈的省级招标挂网,具体定价可参考挂网价格;上市之后,诺和诺德将根据肥胖症患者在全国的分布进行涵盖公立医院、私立医院以及药店等全渠道的布局。
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.